Experts divided on Avrobio’s phase two gene therapy for Fabry disease

shutterstock_164970326
Approved enzyme replacement therapies (ERTs) in Fabry disease have demonstrated Gb3 inclusions reduction, some experts said. Credit: StudioMolekuul on Shutterstock.